William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Myles Minter has given his Buy rating due to a combination of factors surrounding Larimar Therapeutics’ progress and potential in the treatment of Friedreich’s ataxia (FA). The company is actively working towards an accelerated approval filing for their therapy, nomlabofusp, by the second quarter of 2026. Despite recent market fluctuations influenced by regulatory challenges faced by peers, Larimar remains optimistic about the efficacy of their treatment, supported by promising open-label study results.
Minter acknowledges the regulatory uncertainties but emphasizes Larimar’s proactive engagement with the FDA through the START program, which could bolster investor confidence. The company’s recent data presentation demonstrated significant efficacy, and they are on track with their clinical milestones, including building a robust safety database. These developments contribute to a positive outlook for Larimar’s stock, justifying the Buy rating.
According to TipRanks, Minter is a 5-star analyst with an average return of 29.1% and a 59.85% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Biogen, and Larimar Therapeutics.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $22.00 price target.